后天性外耳道狭窄的手术治疗

目的探讨后天性外耳道狭窄的手术治疗方法及效果。方法对26例（27耳）外耳道狭窄行外耳道成形术或厢乳突根治鼓室成型术，取大腿内侧自体游离中厚皮片植皮，碘仿纱条压迫并扩张耳道。结果26例病人27耳随访6个月至8年，24耳外耳道宽敞，无再狭窄；3耳出现轻度狭窄，发生率11．1％（3／27），效果满意。结论对后天性外耳道狭窄的治疗可根据狭窄的原因、部位及程度等不同情况采用外耳道成形、游离中厚皮片移植或同时进行乳突根治鼓室成型术等手术治疗，术后局部换药，即能取得较好效果。     

大黄(庶虫)虫丸治疗囊肿性痤疮的临床疗效评价

目的　观察大黄虫丸治疗囊肿性痤疮的临床疗效。　方法　选择囊肿性痤疮患者 33 例做为治疗组,给予口服大黄虫丸治疗,观察并记录结果。　结果　治疗的总有效率为 90 9%,对照组(P<0 05)。　结论　大黄虫丸对囊肿性痤疮有较好的临床疗效。     

放疗化疗联合治疗局部晚期非小细胞肺癌43例

目的 探讨以顺铂为主的化疗方案加放疗对局部晚期非小细胞肺癌的疗效。方法 86例局部晚期非小细胞肺癌患随机分为治疗组及对照组各43例，放疗方案以CAP、EP、MVP或MOP，每人至少化疗两个周期，化疗后10～14天放射治疗，放疗采用^60Co外照射。结果 治疗组有效率83．7％，中位生存期14．5个月，对照组有效率67．4％，中位生存期10个月，两组不良反应为骨髓抑制、胃肠道反应。结论 以顺铂为主的化疗方案加放疗治疗局部晚期非小细胞肺癌的疗效较高，可提高肿瘤的局部控制率和延长生存期。     

骨水泥和种植体同期植入修复颌骨和牙列缺损的实验研究

目的：探讨高分子材料和种植体同期植入缺损区进行同步骨缺损修复和牙列缺损修复的可行性。方法：以4只杂种狗为研究对象，制备下颌骨长约2．5cm的缺损的动物模型(保留下颌骨下缘)，将骨水泥(聚甲基丙烯酸酯)植入骨缺损，同时将牙种植体植入骨水泥中并调整长轴方向，立即关闭术创。至术后3个月摄X线片，然后处死动物，局部巨检以了解骨水泥同骨组织的结合情况，并制备骨组织切片进行苏木精一伊红染色和甲苯胺蓝染色，以了解植入材料周边骨的生长情况及其对植入材料的反应。结果：术后3个月X线检查见骨缺损区充满骨水泥，骨水泥周边的骨小梁清晰，未见骨吸收或炎症表现，形成良好的骨-骨水泥界面，种植体则依赖其表面的螺纹结构与骨水泥间紧密的机械性嵌合而牢固的成为一体，植入的骨水泥块与周边天然骨结合紧密，无松动现象。植入材料周边局部脱钙骨的苏木精-伊红染色和甲苯胺蓝染色见骨结构正常，同时骨-骨水泥界有新骨形成。结论：骨水泥作为颌骨修复替代材料同期植入种植体是可行的。     

关于发展中医特色的卒中单元的思考

阐述目前中风治疗的概况，介绍国外卒中单元（stroke unit,SU)在中风病人急救和康复治疗中的重要作用和SU的特色、优势及临床实践模式，分析了我国发挥中医优势、建立中西医结合SU的可能性及必要性。     

Inflammatory central nervous system disease in lupus-prone MRL/lpr mice: comparative histologic and immunohistochemical findings

The brains of pathogen-free autoimmune MRL/lpr, NZBWF1 and NZB mice were examined for central nervous system (CNS) inflammation in premoribund 8-week-old animals and at ages when active systemic lupus erythematosus (SLE) was present. CNS inflammation was observed only in MRL/lpr mice. Immunohistochemical studies of brains from young MRL/lpr mice found that infiltrates were composed primarily of CD4+ cells. Older MRL/lpr mice (22 and 26 weeks of age) had CD4+ cells predominantly, but CD8+ and B220+ cells were also present. Perivascular leakage of IgG was a prominent and unexpected finding in the MRL/lpr model. Congenic MRL/+ mice with late-onset autoimmunity had no inflammatory cells in brain tissue, and there was no perivascular staining with IgG or albumin. Our findings suggest that MRL/lpr mice are a useful model for studies of lupus-associated CNS inflammatory disease, and perivascular leakage may be a primary mechanism for entry of IgG into the brain.     

INFLUENCE OF DIET ON FATTY ACID COMPOSITION OF RED CELL AND NEURAL MEMBRANES

Increasing dietary 18:2 n-6/18:3 n-3 causes similar relative changes in fatty acid profiles of phosphatidylethanolamine and phosphatidylcholine from rat neural and erythrocyte membranes.     

多希紫杉醇联合顺铂治疗晚期非小细胞肺癌疗效观察

目的观察和评价多希紫杉醇联合顺铂(DP方案)治疗晚期非小细胞肺癌的疗效和毒性。方法将我科近几年收治的48例晚期非小细胞肺癌患者随机分为治疗组和对照组。治疗组采用多希紫杉醇联合顺铂(DP方案),对照组采用长春瑞滨联合顺铂(NP方案)。2周期化疗后进行疗效、毒性对比研究。结果治疗组和对照组近期有效率分别为45.5%和37.5%,疾病进展时间(TTP)分别为6.3和5.9个月,中位生存期分别为10.1和9.0个月,1年生存率分别为45.8%和39.4%,两组间比较差异均无显著性(P>0.05)。治疗组在恶心呕吐、骨髓抑制等毒性反应发生率方面低于对照组,差异有显著性(P<0.05)。结论多希紫杉醇联合顺铂治疗晚期非小细胞肺癌与NP方案相比较,疗效相似,但毒性反应低于NP组,患者更易耐受,可广泛应用于临床。     

肤纹识别白马藏人的族属

白马藏人是一支有待识别的民族。本文以肤纹作聚类分析,结果表明白马藏人与藏族的距离很大,很有可能是一支独立的民族。     

In vivo anti-melanoma activities of the Melan-A/MART-1101–115 T CD4+ cell peptide

Malignant melanoma causes significant health problems. The identification of tumour-associated antigens has led to novel approaches to increase T cell mediated anti-tumour immune response. Melan-A/MART-1 has been use as target antigen for several T cell based immunotherapeutic treatments. More recently, the critical role of CD4+ T cells in inducing and maintaining anti-tumour immunity has been increasingly recognized. In order to optimize tumour immunotherapy, greater efforts have been concentrated on the identification of tumour antigens presented by MHC class II molecules to CD4+ T cells. In a publication, Tiwari et al. (2004) [1] have identified by a computational approach the 15-mer amino-acid sequence 101–115 (PPAYEKLSAEQSPPP) of the Melan-A/MART-1 as a good target for a vigorous and safe immunotherapy. Therefore, we have investigated the in vivo anti-tumour activity of this peptide in a murine melanoma model. For the prophylactic treatment, 20 μg or 50 μg peptide was subcutaneously injected in mice once a week during 3 weeks before tumour induction. Treatment with 50 μg peptide significantly affected tumour development. Thus, our preliminary data demonstrate potential in vivo prophylactic activity of the 101–115 peptide-based vaccine to control melanoma growth.